
April 30 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:
AMYLYX PHARMACEUTICALS ANNOUNCES FIRST PARTICIPANT DOSED IN PIVOTAL PHASE 3 LUCIDITY TRIAL OF AVEXITIDE IN POST-BARIATRIC HYPOGLYCEMIA
AMYLYX PHARMACEUTICALS INC - LUCIDITY TRIAL RECRUITMENT EXPECTED TO COMPLETE IN 2025, WITH TOPLINE DATA IN FIRST HALF OF 2026
AMYLYX PHARMACEUTICALS INC - EXPECTS CASH RUNWAY THROUGH END OF 2026